Using AI to improve treatment for liver tumors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to develop and validate algorithms that utilize artificial intelligence and machine learning to enhance patient selection, treatment planning, and outcome prediction for individuals undergoing thermal ablation of malignant liver tumors. Over a four-year period, the study will collect comprehensive data on patient demographics, tumor characteristics, and treatment details, along with imaging before, during, and after the procedure. The ultimate goal is to establish thermal ablation as the preferred treatment for most patients with primary or secondary liver tumors through a standardized and accessible workflow.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* 18 years or above
* Candidate for percutaneous thermal liver ablation as discussed in a multidisciplinary tumorboard (MDT)
* Informed consent

Exclusion Criteria:

* Patients lacking capacity to give informed consent.

Where it's running

• Leiden University Medical Centre
  Leiden, Netherlands Recruiting

Study contacts

• Principal investigator: Mark C. Burgmans, MD PhD — Leiden univeristy medical centre
• Study coordinator: Coosje A. M. Verhagen, Drs.
• Email: c.a.m.verhagen@lumc.nl
• Phone: +31-71-5264376

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Assessing blood biomarkers and MRI for liver cancer patients undergoing radiation therapy

  This study is testing if using special MRI scans and blood tests can help doctors keep track of liver health in patients with liver cancer who are getting radiation therapy.

  Recruiting Montefiore Medical Center · The Bronx, New York · NCT06899152

• Comparing methods to increase liver size before surgery

  This study is testing three different ways to help increase liver size before surgery for patients with liver tumors to see which method works best.

  Recruiting Medical University of Warsaw · Warsaw, Masovian Voivodeship · NCT06050200

• BGB-B2033 vs Sorafenib or Lenvatinib for advanced liver cancer

  This study tests whether the investigational drug BGB-B2033 can help people with advanced hepatocellular carcinoma when given after prior PD-1/PD-L1 therapy, compared with the standard medicines sorafenib or lenvatinib.

  Recruiting at 2 sites Phase 3 BeOne Medicines · South Brisbane, Queensland and 1 other locations · NCT07836530

• DRAGON: International registry for patients who had combined portal and hepatic vein embolization before liver surgery

  This registry collects data on patients who had PVE/HVE before liver resection to see if it helps liver regeneration and what factors relate to outcomes.

  Recruiting at 30 sites Maastricht University Medical Center · Chicago, Illinois and 30 other locations · NCT07717437

• Metastatic liver cancer patient registry from multiple Chinese centers

  This is a registry that collects real-world data on adults with liver metastases to understand patterns and prognosis and to support future research.

  Recruiting at 2 sites Anhui Provincial Hospital · Bengbu, Anhui and 2 other locations · NCT07602504

• MRI-guided adaptive single-session radiation for liver tumors (SABR)

  This trial will test a single-session, MRI-guided adaptive high-dose radiation (SABR) for adults with primary or metastatic liver tumors to see if on-table MRI planning and replanning can treat tumors without a separate simulation visit.

  Recruiting Phase 2 Stanford University · Palo Alto, California · NCT07223307

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.